ecrin-mdr-crcClinical2022colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/47501China9ECRIN MDRNot yet recruitingfalsePhase IB clinical study on the tolerance, safety and efficacy of darafenib, trametinib combined with irinotecan and cetuximab in advanced colorectal cancer with BRAF mutationInterventions: experimental group:Darafenitumertinib plus iritiniconcetuximab Primary outcome(s): Maximum tolerated dose Study Design: Cross-sectional2022-09-1547501ChiCTR2200063316